2025, a Transformational Year Marked by Strategic Steps Designed to Enhance Shareholder Value: the Merger with Logan Ridge, Corporate Rebranding and Completion of a Tender Offer  Announces First Quarter 2026 Quarterly Distribution of $0.32 Per Share; Transition to New Monthly Base Distributions of $0.09 Per Share Beginning April 2026 with the Potential for Quarterly Supplemental Distributions; Total Distributions for 2025 of $1.97 Per Share NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) — BCP Investment Corporation (NASDAQ: BCIC) (“BCIC” or “the Company”) announced today its financial results for the fourth quarter and full year ended December 31, 2025. Full Year 2025 MilestonesOn July 15, 2025, the Company successfully completed the merger with Logan Ridge Finance Corporation (“LRFC”) with and into the Company, a major milestone...

~ Surpasses $100 Million in Annual Revenue, First Time in the Company’s History ~ ~ MAUs of 52 Million in Q4, Representing 11% Quarterly Sequential Growth ~ ~ Recently Launched Rumble Shorts Tops 1 Million Daily Unique Video Views ~ ~ On Track to Complete Transformative Acquisition of AI Infrastructure Company, Northern Data, in the Second Quarter of 2026 ~ ~ Northern Data’s GPU Utilization is Expected to Approximate 85% by End of Q1 20261 ~ LONGBOAT KEY, Fla., March 05, 2026 (GLOBE NEWSWIRE) — Rumble Inc. (Nasdaq: RUM), the Freedom-First technology platform, today announced financial results for the fiscal quarter and full year ended December 31, 2025. Q4 2025 Key Highlights and Key ItemsRevenue for the fourth quarter was $27.1 million, a sequential increase of 9% from $24.8 million in the third quarter of 2025. Average global...

TORONTO, March 05, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, today reported financial results for the fourth quarter and full year ended December 31, 2025. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with U.S. generally accepted accounting principles (U.S. GAAP).   Business HighlightsQ4-2025 revenue grew 43% year-over-year and 13% sequentially quarter-over-quarter to a record $6.0 million.Profound’s TULSA-PRO® qualified sales pipeline also continues to grow, and currently stands at 110 new systems being classified within one of the “Verify, Negotiate and Contracting” stages. The...

BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway. Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520’s differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT’s internal KRAS plus PI3Kα breaker program. Clinical readouts expected in the second half of 2026 across all three programs, positioning BBOT for a...

Fourth Quarter 2025 HighlightsRevenue of $90.9 million versus $94.7 million in the prior year period GAAP net income of $5.4 million versus GAAP net income of $2.7 million in the prior year period Adjusted net income1 of $7.5 million versus adjusted net income of $4.8 million in the prior year period Adjusted EBITDA1 of $15.2 million versus Adjusted EBITDA of $13.0 million in the prior year period Flight equipment sales consisted of four engines compared to six engines in the prior year period Feedstock acquisitions of $15.4 million in the quarter2025 Full Year HighlightsRevenue of $335.3 million versus $345.1 million GAAP net income of $8.6 million versus GAAP Net Income of $5.9 million Adjusted net income1 of $15.8 million versus adjusted net income of $9.5 million Adjusted EBITDA1 of $46.1 million versus Adjusted EBITDA of $33.4...

BERKELEY, Calif., March 05, 2026 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 2025 and provided an overview of recent corporate highlights. “2025 was a year of strong execution for Caribou as we advance two potentially best-in-class allogeneic CAR-T cell therapy programs,” said Rachel Haurwitz, PhD, Caribou’s president and CEO. “The vispa-cel ANTLER phase 1 data in second-line LBCL patients demonstrated efficacy and durability on par with autologous CAR-T therapy and solidified our confidence that this program is delivering on the promise of an off-the-shelf CAR-T cell therapy with speed, scalability, and access. We continue to engage with the FDA on the pivotal trial design...

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBITDA for Full Year SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) — Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the fourth quarter and full year ended December 31, 2025. 2025 Fourth Quarter and Full-Year HighlightsHighlights are for the fourth quarter and full year 2025, except where otherwise noted. Total members886,000 at year end, up 55% year over yearRevenue$76 million in the fourth quarter, up 58% year over year $260 million for the full year, up 53% compared with 2024GLP-1 LeadershipOmada has now supported more than 150,000 members on GLP-1s,...

LIMASSOL, Cyprus, March 05, 2026 (GLOBE NEWSWIRE) — GDEV Inc. (NASDAQ: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”) released its preliminary, unaudited financial and operational results for the fourth quarter and twelve months ended December 31, 2025. Fourth quarter 2025 financial highlights:Revenue of $90 million decreased by 8% year-over-year. Selling and marketing expenses of $35 million decreased by 25% year-over-year. Profit for the period, net of tax, of $14 million in Q4 2025 increased vs. $2 million in Q4 2024. Adjusted EBITDA1 of $15 million in Q4 2025 increased vs. $9 million in Q4 2024.Fourth quarter and twelve months 2025 financial performance in comparisonUS$ million Q4 2025 Q4 2024 Change (%) 12M 2025 12M 2024 Change (%)Revenue 90 98 (8%) 404 421 (4%)Platform commissions (18) (21) (13%) (85) (91) (7%)Game...

Initiates 2026 guidance, anticipating another record year BELGRADE, Mont., March 05, 2026 (GLOBE NEWSWIRE) — Bridger Aerospace Group Holdings, Inc. (“Bridger”, “the Company” or “Bridger Aerospace”), (NASDAQ: BAER, BAERW), one of the nation’s largest aerial firefighting companies, today reported financial results for the fourth quarter and year ended December 31, 2025, including positive net income for the full year. Highlights:Revenue for 2025 grew 25% to $122.8 million, surpassing the company’s increased guidance range Positive Net Income for 2025 was $4.1 million, with adjusted EBITDA increasing 21% from 2024 to $45.3 million Completed $331.5 million financing package, including debt refinancing and a $100.0 million delayed draw facility, to bolster financial flexibility and fund strategic fleet expansion amid rising demand...

Thursday, March 05, 2026 PRESS RELEASE: Annual Accounts 2025Good resilience of Savencia in a difficult dairy context   Approval of the merger between Savencia Fromage & Dairy and Savencia Gourmet’s Chocolate activities to accelerate the development of Premium Foodservice   Completion of the acquisition of Quata in BrazilKey figures in €M   31/12/25   % CA   31/12/24   % CA   Changes in %Total Structure Change & IAS 29 Growth OrganicSales 6 957   7 140   -2.6 0.2 -4.3 1.6– Cheese products 4 017 57.7 4 055 56.8 -1.0 0.0 -0.9 0.0– Other dairy products 3 184 45.8 3 328 46.6 -4.3 0.3 -8.4 3.7– Unallocated -245 -3.5 -244 -3.4        Current Operating Profit 210.5 3.0 232.3 3.3 The audit procedures have been carried out and the audit report relating to certification is currently...